Published in BMJ on March 26, 1994
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer (1995) 4.99
Quality of life measurement in patients with oesophageal cancer. Gut (1995) 1.21
Management of oesophageal cancer. BMJ (1994) 0.95
Rethinking breast cancer screening strategies in resource-limited settings. Afr Health Sci (2010) 0.95
Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study. Br J Cancer (1995) 0.92
Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer (1995) 0.84
Surgery for pancreatic cancer. BMJ (1994) 0.75
Cancer of the upper gastrointestinal tract. Palliative chemotherapy unproved in advanced gastric cancer. BMJ (1994) 0.75
Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med (1991) 23.89
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med (1992) 7.40
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg (1985) 7.14
Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg (1990) 7.04
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer (1993) 4.99
Early detection of gastric cancer. BMJ (1990) 4.26
FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol (1992) 2.31
Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. J Clin Oncol (1985) 2.26
Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet (1992) 2.07
Hepatic metastases: interstitial laser photocoagulation with real-time US monitoring and dynamic CT evaluation of treatment. Radiology (1993) 2.03
Growth of asthmatic children during treatment with budesonide: a double blind trial. BMJ (1991) 1.85
Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol (1989) 1.81
Vertebral bone density in children: effect of puberty. Radiology (1988) 1.77
Endosonography and computed tomography of esophageal carcinoma. Preoperative classification compared to the new (1987) TNM system. Gastroenterology (1989) 1.70
Bone turnover during high dose inhaled corticosteroid treatment. Thorax (1991) 1.59
Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J (1980) 1.55
Pylorus preserving pancreatoduodenectomy: an overview. Br J Surg (1990) 1.48
Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol (1990) 1.19
Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer (1993) 1.02
Interaction of genetic and environmental influences on peak bone density. Osteoporos Int (1990) 0.98
Endoscopic palliation for inoperable malignant dysphagia: long term follow up. Gut (1992) 0.92
An investigation of different methods of cell cycle analysis by flow cytometry in rectal cancer. Br J Cancer (1992) 0.91
Unexpected side-effects of inhaled steroids: a case report. Eur J Pediatr (1991) 0.90
Randomized trials in the treatment of cancer of the esophagus. J Clin Oncol (1992) 0.87
Advances in the control of chemotherapy-induced emesis. Ann Oncol (1992) 0.84
Combined-modality therapy in the treatment of local-regional esophageal cancer. Ann Oncol (1992) 0.81
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Insulin biosynthesis: evidence for a precursor. Science (1967) 5.05
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst (1998) 4.65
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol (2002) 3.98
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Biotechnology awareness study, Part 1: Where scientists get their information. Bull Med Libr Assoc (1991) 3.85
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer (1998) 3.36
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol (2009) 3.33
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol (1997) 2.71
Radiographic interpretation by nurse practitioners in a minor injuries unit. J Accid Emerg Med (1996) 2.44
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol (2005) 2.41
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.31
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
From quantity to quality: the central cardiac audit database project. Heart (1999) 2.23
Global impact of influenza virus on cellular pathways is mediated by both replication-dependent and -independent events. J Virol (2001) 2.13
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol (2000) 2.12
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer (1996) 2.11
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet (1987) 2.09
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol (1996) 2.08
Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol (1995) 2.08
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol (1994) 2.02
Detection of ambulatory ischaemia is not of practical clinical value in the routine management of patients with stable angina. A long-term follow-up study. Eur Heart J (1995) 1.97
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer (2005) 1.81
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer (1999) 1.80
Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.68
MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? Br J Cancer (2006) 1.68
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer (2002) 1.66
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol (2012) 1.65
Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut (2003) 1.61
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol (1999) 1.59
Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer (2007) 1.58
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol (2011) 1.51
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer (2008) 1.50
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol (2004) 1.49
Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer (2005) 1.47
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol (2004) 1.46
Detecting t(14;18) in paraffin-embedded lymphoma tissue. Lancet (1989) 1.45
Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer (2002) 1.45
Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol (1994) 1.45
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. Eur J Cancer (2003) 1.45
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol (2007) 1.44
Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer. Eur J Cancer (1998) 1.44
Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. J Clin Oncol (1995) 1.43
Acute effect of oestrogen replacement therapy on treadmill performance in postmenopausal women with coronary artery disease. Eur Heart J (1995) 1.43
Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol (2003) 1.42
Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol (2005) 1.41
Myeloma and benign intracranial hypertension. BMJ (1992) 1.41
Treatment in advanced colorectal cancer: what, when and how? Br J Cancer (2009) 1.40
Prevention and therapy of serous otitis media by oral decongestant: a double-blind study in pediatric practice. Pediatrics (1978) 1.39
Prothrombin mRNA is expressed by cells of the nervous system. Neuron (1991) 1.38
Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci U S A (1991) 1.37
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol (2004) 1.34
Chest pain in women: clinical, investigative, and prognostic features. BMJ (1994) 1.32
Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer (1995) 1.31
Adjuvant therapy in colon cancer--what, when and how? Ann Oncol (2006) 1.30
BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 1.30
Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer (1999) 1.27
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood (1993) 1.27
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol (2009) 1.26
Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res (1991) 1.26
Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs. Br Med J (Clin Res Ed) (1985) 1.25
Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 1.25
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer (2009) 1.25
Chemotherapy for primary gastric lymphoma: does in-patient observation prevent complications? Clin Oncol (R Coll Radiol) (2004) 1.23
Low energy catheter ablation of a posteroseptal accessory pathway associated with a diverticulum of the coronary sinus. Pacing Clin Electrophysiol (1991) 1.23
Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res (1986) 1.19
Long-term follow-up study of survival and recurrence rates following myocardial infarction in exercising and control subjects. Circulation (1972) 1.18
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol (2008) 1.18
Chemotherapy of carcinoma of the stomach. Cancer Treat Rev (1993) 1.16
Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. Eur Radiol (2008) 1.16
Transvenous ablation of atrioventricular conduction with a low energy power source. Br Heart J (1989) 1.15
The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. Br J Cancer (1998) 1.15
Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol (1996) 1.14
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol (1998) 1.14
Comparative genome sequence analysis of the Bpa/Str region in mouse and Man. Genome Res (2000) 1.13
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol (2013) 1.13
The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer (1993) 1.13
Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. Eur J Cancer (2006) 1.12
Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol (2001) 1.12
Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis. Lancet (1989) 1.11
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer (2005) 1.11
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol (2011) 1.11
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer (2003) 1.10
Circadian variation of total ischaemic burden and its alteration with anti-anginal agents. Lancet (1988) 1.10
A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer (2002) 1.09
Right phrenic nerve palsy as a complication of indwelling central venous catheters. Thorax (1997) 1.08
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer (1999) 1.07
Rapid access multidisciplinary lymph node diagnostic clinic: analysis of 550 patients. Br J Cancer (2003) 1.05
Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. Br J Cancer (1991) 1.05